PYC Therapeutics has dosed the first patient in a Phase 1b Multiple Ascending Dose study testing PYC-003 in people with polycystic kidney disease.

Moderna has opened applications for the 2026 Moderna Australia Fellowship, a program that will fund and mentor early-career Australian scientists for two years as they pursue mRNA research and innovation.

AdAlta has raised $2.5 million from sophisticated investors to accelerate development of its lead CAR T therapy, BZDS1901, and to progress manufacturing and regulatory milestones in Australia and the United States.

The cash injection is intended to strengthen Cynata’s runway through two near-term clinical milestones and to position the company for commercial partnering and regulatory engagement after results are released.

Arovella Therapeutics has updated investors, advising that a requisitioning shareholder had served a notice under the Corporations Act seeking the removal of two directors and that the company would undergo a significant board refresh.

Botanix Pharmaceuticals has announced the promotion of Paul Seaback to Chief Operating Officer, a move the commercial dermatology company said will strengthen day-to-day operations and drive strategic growth across its Philadelphia and Phoenix businesses.

Entropy Neurodynamics has reported Phase 2a results suggesting a potential new direction for patients with treatment-resistant irritable bowel syndrome.

Telix Pharmaceuticals is positioning a new generation of PSMA-targeted therapies to overcome limitations seen when first-generation radioligand therapies are moved into earlier lines of prostate cancer care.

Syntara CEO Gary Phillips said, “We’re very grateful for the strong support from our shareholders and new investors in this capital raising, stemming from the positive FDA review of our clinical development plan and Phase 2b protocol for amsulostat."

Mesoblast has reached a key milestone in its bid to bring a non-opioid, disease-modifying treatment for chronic low back pain to market, announcing that the pivotal Phase 3 trial of rexlemestrocel L has hit its patient recruitment target.

AVITA Medical has secured regulatory clearance in Australia and a WAND listing in New Zealand for RECELL GO, its next-generation system for preparing RECELL Spray On Skin.

Emyria has reached an agreement with Matilda Healthcare to open an Empax clinic at Matilda Nepean Private Hospital in Kingswood, expanding the company's presence in New South Wales and increasing its national footprint.

A new analysis released during World Immunisation Week 2026 has sharpened the focus on a persistent weakness in Australia’s health system, highlighting a gap between strong early-stage vaccine research and its translation into real-world outcomes.

Under the agreement, CLEO will build on its existing work using Bio-Techne’s Ella platform, which the company has been using in-house and which has demonstrated the ability to deliver CLEO’s biomarker panel with high sensitivity, precision, and reproducibility.

The company said VP-001 has the potential to become the first approved treatment for patients with RP11, a genetic eye disease with no available therapies.

Algorae said the collaboration establishes a framework for joint prioritisation of products based on regulatory pathways, supply readiness and market access considerations.

Managing director Paul Rennie said the level of investor support underscored confidence in the company’s Phase 3 program and its upcoming interim analysis.